Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-10017799-B2
Application number	US-201615360763-A
Country	US
Kind code	B2
Filing date	Nov 23, 2016
Priority date	Mar 15, 2013
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.

First claim

What is claimed is:

1. A method of preparing a benzylisoquinoline alkaloid product, the method comprising:
culturing an engineered bacterial cell under conditions suitable for protein production, wherein the engineered bacterial cell is an opioid-producing engineered bacterial cell, wherein the engineered bacterial cell comprises a plurality of heterologous coding sequences for encoding at least three heterologous enzymes within a pathway for producing the benzylisoquinoline alkaloid product, and wherein at least one heterologous coding sequence of the plurality of heterologous coding sequences encodes an enzyme that is within a pathway that converts a thebaine to the benzylisoquinoline alkaloid product, wherein the engineered microbial cell is a bacteria cell;
adding a starting compound to the cell culture; and
recovering the benzylisoquinoline alkaloid product from the cell culture, wherein the benzylisoquinoline alkaloid product is selected from the group consisting of a neopinone, neopine, neomorphine, codeinone, codeine, morphine, oripavine, morphinone, hydrocodone, 14-hydroxycodeinone, dihydrocodeine, oxycodone, 14-hydroxy codeine, hydromorphone, and dihydromorphine.

2. The method according to claim 1 , wherein the engineered microbial bacterial cell comprises:
three or more heterologous coding sequences for encoding one or more enzymes that are selected from the group consisting of Thebaine 6-0 demethylase, Codeinone reductase, Codeine O-demethylase, Morphine dehydrogenase, and Morphine reductase.

3. The method according to claim 2 , wherein the engineered bacterial cell comprises heterologous coding sequences for encoding two enzymes that are involved in the pathway that converts a thebaine into the benzylisoquinoline alkaloid product, each of the two enzymes selected from the group consisting of Thebaine 6-0 demethylase, Codeinone reductase, Codeine O-demethylase, Morphine dehydrogenase.

4. The method according to claim 3 , wherein the two enzymes are operably connected along the pathway that converts a thebaine into the benzylisoquinoline alkaloid product.

5. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of neopine, neomorphine, codeinone, codeine, morphine, oripavine, morphinone, hydromorphone, dihydromorphine, hydrocodone, dihydrocodeine, 14-hydroxycodeinone, oxycodone, and 14-hydroxycodeine.

6. The method of claim 1 , wherein the benzylisoquinoline alkaloid product is produced using one or more of N-methylation, acetalization, hydroxylation, oxidation, reduction, cyclization, dehydration, O-alkylation, demethylation, and isomerization.

7. The method of claim 1 , wherein at least one heterologous coding sequence of the plurality of heterologous coding sequences encodes an enzyme that is selected from the group consisting of Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, 4′-O-methyltransferase, and Cytochrome P450 80B1.

8. A method of preparing a benzylisoquinoline alkaloid product, the method comprising:
culturing an engineered bacterial cell or an engineered yeast cell under conditions suitable for protein production, wherein the engineered bacterial cell or an engineered yeast cell is an opioid-producing engineered bacterial cell or an engineered yeast cell, wherein the engineered bacterial cell or an engineered yeast cell comprises at least three heterologous coding sequences for encoding a first, second, and third enzyme within a pathway for producing the benzylisoquinoline alkaloid product, wherein the first, second, and third enzymes are operably connected along the pathway, and wherein one enzyme of the first, second, and third enzymes is Salutaridine synthase;
adding a starting compound to the cell culture; and
recovering the benzylisoquinoline alkaloid product from the cell culture, wherein the benzylisoquinoline alkaloid product is selected from the group consisting of a salutaridine, salutaridinol, 7-O-acetylsalutaridinol, thebaine, neopinone, neopine, neomorphine, codeinone, codeine, morphine, oripavine, morphinone, hydrocodone, 14-hydroxycodeinone, dihydrocodeine, oxycodone, 14-hydroxycodeine, hydromorphone, and dihydromorphine.

9. The method of claim 8 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of salutaridine, salutaridinol, 7-O-acetylsalutaridinol, thebaine, neopine, neomorphine, codeinone, codeine, morphine, oripavine, morphinone, hydromorphone, dihydromorphine, hydrocodone, dihydrocodeine, 14-hydroxycodeinone, oxycodone, and 14-hydroxycodeine.

10. The method of claim 8 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of neopine, neomorphine, codeinone, codeine, morphine, oripavine, morphinone, hydromorphone, dihydromorphine, 14-hydroxycodeinone, oxycodone, and 14-hydroxycodeine.

11. The method of claim 8 , wherein the benzylisoquinoline alkaloid product is produced using one or more of N-methylation, acetalization, hydroxylation, oxidation, reduction, cyclization, dehydration, O-alkylation, demethylation, and isomerization.

12. The method of claim 8 , wherein two enzymes of the first, second, and third enzymes involved in the pathway that produces the benzylisoquinoline alkaloid product are selected from the group consisting of Salutaridine Reductase, Salutaridinol 7-O-acetyltransferase, Norcoclaurine 6-O-methyltransferase, Coclaurine-N-methyltransferase, 4′-O- methyltransferase, Cytochrome P450 80B1, Thebaine 6-O demethylase, Codeinone reductase, Codeine O-demethylase, Morphine dehydrogenase, and Morphine reductase.

13. The method of claim 8 , wherein the engineered bacterial cell or an engineered yeast cell is a bacteria cell.

14. The method of claim 8 , wherein the engineered bacterial cell or an engineered yeast cell is a yeast cell.

15. A method of preparing a benzylisoquinoline alkaloid product, the method comprising:
culturing an engineered yeast cell under conditions suitable for protein production, wherein the engineered yeast cell is an opioid-producing engineered microbial cell, wherein the engineered yeast cell comprises a plurality of heterologous coding sequences for encoding a plurality of enzymes within a pathway for producing the benzylisoquinoline alkaloid product, and wherein at least one heterologous coding sequence of the plurality of heterologous coding sequences encodes an enzyme that is within a pathway that converts a thebaine to the benzylisoquinoline alkaloid product;
adding a starting compound to the cell culture; and
recovering the benzylisoquinoline alkaloid product from the cell culture, wherein the benzylisoquinoline alkaloid product is selected from the group consisting of a neopinone, oripavine, and 14-hydroxycodeinone.

16. The method according to claim 15 , wherein the engineered yeast cell comprises:
one or more heterologous coding sequences for encoding one or more enzymes that are selected from the group consisting of Thebaine 6-O demethylase and Codeine O-demethylase.

17. The method of claim 15 , wherein the benzylisoquinoline alkaloid product is selected from the group consisting of oripavine and 14-hydroxycodeinone.

18. The method of claim 15 , wherein the benzylisoquinoline alkaloid product is produced using one or more of N-methylation, acetalization, hydroxylation, oxidation, reduction, cyclization, dehydration, O-alkylation, demethylation, and isomerization.

19. The method of claim 15 , wherein at least one heterologous coding sequence of the plurality of heterologous coding sequences encodes an en

Assignees

• Univ Leland Stanford Junior

Inventors

• Smolke Christina D
• Thodey Catherine
• Trenchard Isis
• Galanie Stephanie

Classifications

• C12Y201/0114

  (S)-Coclaurine-N-methyltransferase (2.1.1.140) · CPC title

• C12Y201/01116

  3'-Hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase (2.1.1.116) · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12N9/1007 Primary

  Methyltransferases (general) (2.1.1.) · CPC title

• C12Y201/01128

  (RS)-Norcoclaurine 6-O-methyltransferase (2.1.1.128) · CPC title